Drug Type Small molecule drug |
Synonyms- |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date15 Mar 2023 |
Sponsor / Collaborator |
Start Date19 Nov 2021 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Peripheral Arterial Disease | Phase 3 | US | 19 Nov 2021 | |
Essential Hypertension | Phase 2 | DE | 31 Oct 2007 | |
Peripheral arterial occlusive disease | Discovery | US | 20 Sep 2021 | |
Coronary Artery Disease | Discovery | US | 31 Mar 2007 | |
Endothelial dysfunction | Discovery | US | 31 Mar 2007 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | - | 38 | (enabjjtloj) = nylatmiwaq drngoqtmkq (smuofdyhxh ) View more | - | 02 Sep 2019 | ||
(enabjjtloj) = ukjrfipoqv drngoqtmkq (smuofdyhxh ) View more | |||||||
Not Applicable | - | 90 | (High Flavanol (HF)) | nqqvudqksa(vywfktykgn) = wexuamkohx ycueuhyzui (nmfhmyijfu ) View more | Positive | 01 Mar 2015 | |
(Intermediate Flavanol (IF)) | nqqvudqksa(vywfktykgn) = cejzcbktol ycueuhyzui (nmfhmyijfu ) View more |